FLIP as a therapeutic target in cancer

Luke Humphreys, Margarita Espona-Fiedler, Daniel B Longley

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

One of the classic hallmarks of cancer is disruption of cell death signalling. Inhibition of cell death promotes tumour growth and metastasis, causes resistance to chemo- and radiotherapies as well as targeted agents, and is frequently due to overexpression of antiapoptotic proteins rather than loss of pro-apoptotic effectors. FLIP is a major apoptosis-regulatory protein frequently overexpressed in solid and haematological cancers, in which its high expression is often correlated with poor prognosis. FLIP, which is expressed as long (FLIP(L)) and short (FLIP(S)) splice forms, achieves its cell death regulatory functions by binding to FADD, a critical adaptor protein which links FLIP to the apical caspase in the extrinsic apoptotic pathway, caspase-8, in a number of cell death regulating complexes, such as the death-inducing signalling complexes (DISCs) formed by death receptors. FLIP also plays a key role (together with caspase-8) in regulating another form of cell death termed programmed necrosis or 'necroptosis', as well as in other key cellular processes that impact cell survival, including autophagy. In addition, FLIP impacts activation of the intrinsic mitochondrial-mediated apoptotic pathway by regulating caspase-8-mediated activation of the pro-apoptotic Bcl-2 family member Bid. It has been demonstrated that FLIP can not only inhibit death receptor-mediated apoptosis, but also cell death induced by a range of clinically relevant chemotherapeutic and targeted agents as well as ionizing radiation. More recently, key roles for FLIP in promoting the survival of immunosuppressive tumour-promoting immune cells have been discovered. Thus, FLIP is of significant interest as an anticancer therapeutic target. In this article, we review FLIP's biology and potential ways of targeting this important tumour and immune cell death regulator.

Original languageEnglish
Pages (from-to)4104-4123
Number of pages20
JournalThe FEBS Journal
Volume285
Issue number22
Early online date28 May 2018
DOIs
Publication statusPublished - Nov 2018

Fingerprint

Cell death
Cell Death
Caspase 8
CASP8 and FADD-Like Apoptosis Regulating Protein
Neoplasms
Tumors
Death Domain Receptors
Therapeutics
Death Domain Receptor Signaling Adaptor Proteins
Chemical activation
Apoptosis Regulatory Proteins
Chemotherapy
Ionizing radiation
Autophagy
Radiotherapy
Immunosuppressive Agents
Caspases
Ionizing Radiation
Cell Survival
Proteins

Keywords

  • Cflar
  • DISC
  • FLIP
  • apoptosis
  • autophagy
  • cancer
  • necroptosis
  • resistance

Cite this

Humphreys, Luke ; Espona-Fiedler, Margarita ; Longley, Daniel B. / FLIP as a therapeutic target in cancer. In: The FEBS Journal. 2018 ; Vol. 285, No. 22. pp. 4104-4123.
@article{8cb10cc1f86f4922955ba34f3ecb1ca2,
title = "FLIP as a therapeutic target in cancer",
abstract = "One of the classic hallmarks of cancer is disruption of cell death signalling. Inhibition of cell death promotes tumour growth and metastasis, causes resistance to chemo- and radiotherapies as well as targeted agents, and is frequently due to overexpression of antiapoptotic proteins rather than loss of pro-apoptotic effectors. FLIP is a major apoptosis-regulatory protein frequently overexpressed in solid and haematological cancers, in which its high expression is often correlated with poor prognosis. FLIP, which is expressed as long (FLIP(L)) and short (FLIP(S)) splice forms, achieves its cell death regulatory functions by binding to FADD, a critical adaptor protein which links FLIP to the apical caspase in the extrinsic apoptotic pathway, caspase-8, in a number of cell death regulating complexes, such as the death-inducing signalling complexes (DISCs) formed by death receptors. FLIP also plays a key role (together with caspase-8) in regulating another form of cell death termed programmed necrosis or 'necroptosis', as well as in other key cellular processes that impact cell survival, including autophagy. In addition, FLIP impacts activation of the intrinsic mitochondrial-mediated apoptotic pathway by regulating caspase-8-mediated activation of the pro-apoptotic Bcl-2 family member Bid. It has been demonstrated that FLIP can not only inhibit death receptor-mediated apoptosis, but also cell death induced by a range of clinically relevant chemotherapeutic and targeted agents as well as ionizing radiation. More recently, key roles for FLIP in promoting the survival of immunosuppressive tumour-promoting immune cells have been discovered. Thus, FLIP is of significant interest as an anticancer therapeutic target. In this article, we review FLIP's biology and potential ways of targeting this important tumour and immune cell death regulator.",
keywords = "Cflar, DISC, FLIP, apoptosis, autophagy, cancer, necroptosis, resistance",
author = "Luke Humphreys and Margarita Espona-Fiedler and Longley, {Daniel B}",
note = "{\circledC} 2018 Federation of European Biochemical Societies.",
year = "2018",
month = "11",
doi = "10.1111/febs.14523",
language = "English",
volume = "285",
pages = "4104--4123",
journal = "FEBS journal",
issn = "1742-464X",
publisher = "Wiley-Blackwell",
number = "22",

}

FLIP as a therapeutic target in cancer. / Humphreys, Luke; Espona-Fiedler, Margarita; Longley, Daniel B.

In: The FEBS Journal, Vol. 285, No. 22, 11.2018, p. 4104-4123.

Research output: Contribution to journalReview article

TY - JOUR

T1 - FLIP as a therapeutic target in cancer

AU - Humphreys, Luke

AU - Espona-Fiedler, Margarita

AU - Longley, Daniel B

N1 - © 2018 Federation of European Biochemical Societies.

PY - 2018/11

Y1 - 2018/11

N2 - One of the classic hallmarks of cancer is disruption of cell death signalling. Inhibition of cell death promotes tumour growth and metastasis, causes resistance to chemo- and radiotherapies as well as targeted agents, and is frequently due to overexpression of antiapoptotic proteins rather than loss of pro-apoptotic effectors. FLIP is a major apoptosis-regulatory protein frequently overexpressed in solid and haematological cancers, in which its high expression is often correlated with poor prognosis. FLIP, which is expressed as long (FLIP(L)) and short (FLIP(S)) splice forms, achieves its cell death regulatory functions by binding to FADD, a critical adaptor protein which links FLIP to the apical caspase in the extrinsic apoptotic pathway, caspase-8, in a number of cell death regulating complexes, such as the death-inducing signalling complexes (DISCs) formed by death receptors. FLIP also plays a key role (together with caspase-8) in regulating another form of cell death termed programmed necrosis or 'necroptosis', as well as in other key cellular processes that impact cell survival, including autophagy. In addition, FLIP impacts activation of the intrinsic mitochondrial-mediated apoptotic pathway by regulating caspase-8-mediated activation of the pro-apoptotic Bcl-2 family member Bid. It has been demonstrated that FLIP can not only inhibit death receptor-mediated apoptosis, but also cell death induced by a range of clinically relevant chemotherapeutic and targeted agents as well as ionizing radiation. More recently, key roles for FLIP in promoting the survival of immunosuppressive tumour-promoting immune cells have been discovered. Thus, FLIP is of significant interest as an anticancer therapeutic target. In this article, we review FLIP's biology and potential ways of targeting this important tumour and immune cell death regulator.

AB - One of the classic hallmarks of cancer is disruption of cell death signalling. Inhibition of cell death promotes tumour growth and metastasis, causes resistance to chemo- and radiotherapies as well as targeted agents, and is frequently due to overexpression of antiapoptotic proteins rather than loss of pro-apoptotic effectors. FLIP is a major apoptosis-regulatory protein frequently overexpressed in solid and haematological cancers, in which its high expression is often correlated with poor prognosis. FLIP, which is expressed as long (FLIP(L)) and short (FLIP(S)) splice forms, achieves its cell death regulatory functions by binding to FADD, a critical adaptor protein which links FLIP to the apical caspase in the extrinsic apoptotic pathway, caspase-8, in a number of cell death regulating complexes, such as the death-inducing signalling complexes (DISCs) formed by death receptors. FLIP also plays a key role (together with caspase-8) in regulating another form of cell death termed programmed necrosis or 'necroptosis', as well as in other key cellular processes that impact cell survival, including autophagy. In addition, FLIP impacts activation of the intrinsic mitochondrial-mediated apoptotic pathway by regulating caspase-8-mediated activation of the pro-apoptotic Bcl-2 family member Bid. It has been demonstrated that FLIP can not only inhibit death receptor-mediated apoptosis, but also cell death induced by a range of clinically relevant chemotherapeutic and targeted agents as well as ionizing radiation. More recently, key roles for FLIP in promoting the survival of immunosuppressive tumour-promoting immune cells have been discovered. Thus, FLIP is of significant interest as an anticancer therapeutic target. In this article, we review FLIP's biology and potential ways of targeting this important tumour and immune cell death regulator.

KW - Cflar

KW - DISC

KW - FLIP

KW - apoptosis

KW - autophagy

KW - cancer

KW - necroptosis

KW - resistance

UR - http://www.scopus.com/inward/record.url?scp=85056599366&partnerID=8YFLogxK

U2 - 10.1111/febs.14523

DO - 10.1111/febs.14523

M3 - Review article

C2 - 29806737

VL - 285

SP - 4104

EP - 4123

JO - FEBS journal

JF - FEBS journal

SN - 1742-464X

IS - 22

ER -